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CXC Receptor-2 Knockout Genotype Increases
X-Linked Inhibitor of Apoptosis Protein and Protects
Mice From Acetaminophen Hepatotoxicity
Bin Hu and Lisa M. Colletti
Although acetaminophen is a commonly used analgesic, it can be highly hepatotoxic. This
study seeks to further investigate the mechanisms involved in acetaminophen-induced hepa-
totoxicity and the role of chemokine (C-X-C motif) receptor 2 (CXCR2) receptor/ligand
interactions in the liver’s response to and recovery from acetaminophen toxicity. The CXC
chemokines and their receptor, CXCR2, are important inflammatory mediators and are
involved in the control of some types of cellular proliferation. CXCR2 knockout mice
exposed to a median lethal dose of acetaminophen had a significantly lower mortality rate
than wild-type mice. This difference was at least partially attributable to a significantly
decreased rate of apoptosis in CXCR2 knockout mice versus wild-type mice; there were no
differences seen in hepatocyte proliferation in wild-type mice versus knockout mice after this
injury. Conclusion: The decreased rate of apoptosis in the knockout mice correlated with an
almost undetectable and significantly decreased level of activated caspase-3 and significantly
increased levels of X-linked inhibitor of apoptosis protein, which also correlated with
increased levels of nuclear factor kappa B p52 and decreased levels of c-Jun N-terminal ki-
nase; this provides a possible mechanism for the decrease in apoptosis seen in CXCR2
knockout mice. (HEPATOLOGY 2010;52:691-702)
A
cute liver failure is common in patients admit-
ted to the intensive care unit; in approximately
20% of acute hepatic failure cases, the liver
injury is related to acetaminophen (APAP) toxicity.1
The mechanism of APAP-induced liver injury involves
the cytochrome P-450–generated metabolite N-acetyl-
p-benzoquinone imine, which causes glutathione
(GSH) depletion, impairs mitochondrial respiration,
and interferes with calcium homeostasis, although the
actual events resulting in cell death are not well
understood.2
Apoptosis occurs in all cells and is regulated by cel-
lular death and cellular survival signals. Imbalances in
these signals can be lethal and likely play a role in
many pathophysiological processes. X-linked inhibitor
of apoptosis protein (XIAP), which belongs to the in-
hibitor of apoptosis protein (IAP) family, binds to and
inhibits caspase-3 and caspase-9 and protects endothe-
lial cells against tumor necrosis factor-alpha–mediated
apoptosis.3 XIAP also inhibits apoptosis by another
mechanism: a positive feedback loop that furthers nu-
clear factor kappa B (NF-jB) activation.3,4
This article investigates chemokine (C-X-C motif )
receptor 2 (CXCR2) signaling in the apoptotic
response to hepatic APAP toxicity in the mouse. The
CXC chemokines play a role in many inflammatory
and regenerative processes and are the major ligands
for the CXCR2 receptor. Studies have demonstrated
that CXC chemokines, including interleukin-8, macro-
phage inflammatory protein-2 (MIP2), and keratino-
cyte (KC) among others, have direct effects on hepato-
cytes. The CXCR2 receptor is expressed on
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hepatocytes,5 and that finding has been confirmed in
this study. In models of both partial hepatectomy and
APAP toxicity, CXCR2/ligand interactions promote
hepatocyte proliferation and liver regeneration.4,6,7 In
contrast, other investigators have found that CXCR2
ligands can be hepatotoxic.8
Materials and Methods
Animal Model. CXCR2-targeted mutant mice were
generated by the mating of heterozygote C.129S2(B6)-
Il8rbtm1Mwm/J (Il8rbtm1Mwm/Il8rbþ) mice (Jackson
Laboratory, Bar Harbor, MN) in the University of
Michigan animal facility. CXCR2 mutant
(Il8rbtm1Mwm/Il8rbtm1Mwm) mice and CXCR2 wild-
type (Il8rbþ/Il8rbþ) mice were used in all experiments;
wild-type and mutant mice were based on the mouse
129 strain. All experiments were performed in compli-
ance with the standards for animal use and care set by
the University of Michigan’s committee on the use and
care of animals.
Animals were fasted overnight, and APAP or an equal
volume of phosphate-buffered saline (PBS) was admin-
istered intraperitoneally.9 For mortality experiments,
animals received 750 or 1000 mg/kg APAP; for all
other experiments, 375 mg/kg was used. On the basis
of previous experiments with this strain of mouse, 750
mg/kg APAP is approximately the median lethal dose,
and 375 mg/kg is approximately the 25% lethal dose.
To confirm that apoptosis is important in the
APAP-induced liver injury in this model, additional
experiments were performed with the pancaspase in-
hibitor Q-VD-OPh. Q-VD-OPh is more effective at
preventing apoptosis than other inhibitors, such as
ZVAD-fmk and Boc-D-fmk, and is nontoxic to cells,
even at high doses.10 This compound prevents apopto-
sis mediated by the three major apoptotic pathways:
caspase-9/3, caspase-8/10, and caspase-12.10 Q-VD-
OPh (50 mg/kg; R&D Systems, Minneapolis, MN)
was administered 1 hour before APAP injection; con-
trol animals received an equivalent dose of vehicle.
Animals were then sacrificed according to protocol,
and apoptosis was measured by terminal deoxynucleo-
tidyl transferase–mediated deoxyuridine triphosphate
nick-end labeling (TUNEL) staining and DNA frag-
mentation assay.
Aspartate Aminotransferase (AST) and Alanine
Aminotransferase (ALT) Assay. Serum AST and ALT
were measured in CXCR2 knockout and wild-type mice
24, 48, and 72 hours after APAP or PBS administration.
Animals were sacrificed, their blood was collected, and
the serum was separated from the clotted blood by cen-
trifugation at 4000 rpm for 15 minutes at 4C. ALT and
ASTwere measured with a Diagnostics ALT and AST test
kit from Sigma Chemical Co. (St. Louis, MO).
GSH Assay. Mouse livers were perfused with a perfu-
sion medium (Gibco, Grand Island, NY) to remove intra-
vascular blood. Ten milligrams of liver tissue was homoge-
nized in 1 mL of PBS containing 2 mM ethylene diamine
tetraacetic acid. Fifty microliters of tissue extract was used
for GSH measurement. GSH was measured according to
the manufacturer’s instructions with a GSH assay kit
(Promega, Madison, WI). Luminescence was detected
with a Synergy 2 multimode microplate reader with Gen5
data analysis software (BioTek, Winooski, VT).
DNA Fragmentation Assay. DNA was extracted
from 25 mg of mouse liver. Total DNA purification
was performed with a DNeasy blood and tissue kit
(Qiagen, Germantown, MA) according to the manu-
facturer’s instructions. RNA was eliminated by incuba-
tion in 5 lg/mL RNase (Roche, Indianapolis, IN). A
1.5-lg DNA aliquot was loaded onto 1.5% agarose
gel for separation to assess for DNA fragmentation.
TUNEL Staining. TUNEL staining was conducted
with an in situ apoptosis detection kit from R&D Sys-
tems according to the manufacturer’s instructions. Six
to seven animals were used per time point per treat-
ment group. At least 1000 cells (TUNEL-positive cells
and TUNEL-negative cells) were counted in each of
eight separate low-power fields for each animal, and
the percentage of TUNEL-positive cells was calculated.
In Vivo Measurement of Hepatocyte Proliferation
by Bromodeoxyuridine (BrdU) Incorporation. Two
hours prior to sacrifice, animals received 30 lg of
BrdU/g of body weight intraperitoneally. Liver speci-
mens were obtained, fixed in 4% paraformaldehyde,
processed for histological analysis, and stained with the
Amersham cell proliferation kit (Amersham Pharmacia
Biotech, Ltd., United Kingdom). BrdU incorporation
was measured at 24, 36, 48, and 72 hours. There were
four to seven mice per treatment group per time point.
At least 1000 cells (BrdU-positive cells and BrdU-neg-
ative cells) were counted in each of eight separate low-
power fields for each animal, and the percentage of
BrdU-positive cells was calculated.
Cytoplasmic and Nuclear Protein Extraction. He-
patic cytoplasmic and nuclear proteins were extracted
with the NE-PER nuclear and cytoplasmic extraction
reagent kit (Pierce Biotechnology, Rockford, IL)
according to the manufacturer’s instructions.
Immunoprecipitation and Western Blot Analysis.
Liver samples were homogenized in a radioimmuno-
precipitation assay buffer (50 mM trishydroxymethyl-
692 HU AND COLLETTI HEPATOLOGY, August 2010
aminomethane–hydrochloric acid, pH 7.4, 150 mM so-
dium chloride, 1% Nonidet P40, 0.1% sodium dodecyl
sulfate, 0.25% sodium deoxycholate, 1 mM ethylene
diamine tetraacetic acid, and protease and phosphatase
inhibitors). Four hundred micrograms of protein was
used for immunoprecipitation. The lysate was precleared
with 1 lg of isotype immunoglobulin G (IgG) and 50
lL of protein A/G agarose at 4C for 1 hour. Five
micrograms of an immunoprecipitating antibody or iso-
type IgG was added to the supernatant, and it was
rocked overnight at 4C. Next, 50 lL of protein agarose
was added, and the mixture was rocked for 2 hours at
4C. The protein bound to the agarose conjugate was
centrifuged, and the pellet was washed three times with
a radioimmunoprecipitation assay buffer. Ten microliters
of a 4 sodium dodecyl sulfate–polyacrylamide gel elec-
trophoresis (SDS-PAGE) sample buffer and 5 lL of 1
M dithiothreitol were added to the pellet, and the sam-
ple was boiled for 5 minutes and centrifuged. The su-
pernatant was saved for SDS-PAGE. Fifty micrograms
of the protein lysate was subjected to SDS-PAGE under
reducing conditions and transferred to polyvinylidene
fluoride membranes. Blots were blocked in a 5% milk
solution and exposed to anti-mouse first antibodies over-
night at 4C. First, antibodies were reacted with horse-
radish peroxidase–conjugated secondary antibodies. All
membranes were visualized with West Pico chemilumi-
nescent substrate (Pierce Biotechnology). Gel-Pro Ana-
lyzer software (Media Cybernetics, Bethesda, MD) was
used to quantify the bands obtained via western blotting.
The band optical density was normalized to the optical
density of the loading control band.
Reagents for Immunoprecipitation, Western Blot
Analysis, and Flow Cytometry. Antibodies for cas-
pase-3, caspase-9, B cell lymphoma 2 (Bcl-2), B cell
lymphoma extra large (Bcl-XL), phosphorylated stress-
activated protein kinase (SAPK)/c-Jun N-terminal ki-
nase (JNK; T183/Y185), and SAPK/JNK were pur-
chased from Cell Signaling Technology, Inc. (Danvers,
MA). Monoclonal anti-human/mouse cellular inhibitor
of apoptosis protein 2 (cIAP2), XIAP, phycoerythrin-
labeled anti-CXCR2, and phycoerythrin-labeled rat
IgG2a were purchased from R&D Systems. Glyceral-
dehyde 3-phosphate dehydrogenase (GAPDH), NF-jB
p65, NF-jB p52, anti-phosphoserine, horseradish per-
oxidase–conjugated goat anti-mouse IgG, and horse-
radish peroxidase–conjugated goat anti-rabbit IgG
were purchased from Santa Cruz Biotechnology, Inc.
(Santa Cruz, CA).
Hepatocyte Isolation. Primary hepatocytes were iso-
lated by collagenase perfusion. Anesthesia was induced
with isoflurane inhalation, laparotomy was performed,
and the inferior vena cava was cannulated with a 26-
gauge angiocatheter. A liver perfusion buffer (Gibco)
was used to flush the liver of intravascular blood
(3 mL/minute for 10 minutes). This was followed by
the infusion of a liver digest buffer (Gibco; 3 mL/mi-
nute for 10 minutes). The liver was excised from the
animal, placed in a Petri dish, minced into 1-mm
pieces, and gently agitated so that the cells would be
dispersed in the wash buffer (Gibco). The cell suspen-
sion was filtered and washed two times at 50g at 4C
for 5 minutes. Cells were immediately used for
reverse-transcription polymerase chain reaction (RT-
PCR) or flow cytometry.
RNA Extraction and RT-PCR. Hepatocytes were
isolated as described previously. Mouse neutrophils
were isolated from the pooled blood of three mice by
differential gradient centrifugation over Percoll
(Gibco). Total RNA from hepatocytes or neutrophils
was isolated with an RNeasy mini kit (Qiagen) accord-
ing to the manufacturer’s instructions. The polymerase
chain reaction (PCR) primers were designed with
Primer Premier software (Premier Biosoft Interna-
tional) to cross exon 1 and exon 2. The sense primer
was 50-TGCTCACAAACAGCGTCGTA-30. The anti-
sense primer was 50-TCAGGGCAAAGAACAGGTCA-30.
Reverse transcription was performed with the Quan-
tiTect reverse-transcription kit (Qiagen). The extracted
RNA was on-column DNase-digested (RNase-free
DNase set, Qiagen), and 1 lg of total RNA was
reverse-transcribed into complementary DNA with the
QuantiTect reverse-transcription kit (Qiagen). Real-
time PCR was performed in a SYBR Green PCR mas-
ter mix (Bio-Rad, Hercules, CA) with a Bio-Rad iCy-
cler iQ multicolor real-time PCR detection system
according to the following protocol: initial activation
at 95C for 15 minutes, 40 cycles at 94C for 15 sec-
onds, 55C for 30 seconds, and 72C for 30 seconds.
Amplification specificity was checked by melting curve
analysis and agarose gel electrophoresis.
Flow Cytometry. Hepatocytes were harvested and
immediately studied with flow cytometry for CXCR2
expression. Cells were washed twice in a staining
buffer (Difco, Detroit, MI), resuspended in 100 lL of
the staining buffer, incubated for 15 minutes at 4C
with anti-mouse CD16/32 to block Fc receptors, and
incubated for 30 minutes at 4C with phycoerythrin-
labeled anti-CXCR2 or phycoerythrin-labeled rat
IgG2a. Final antibody concentrations were 1 to 2 lg/
100 lL of cell solution. After incubation, cells were
washed twice in the staining buffer and analyzed. Flow
cytometry was performed with a FACScan cytometer
(Becton Dickinson, Mountain View, CA). Data were
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collected and analyzed with CellQuest software. At
least 10,000 cells were analyzed to determine cell-sur-
face CXCR2 expression.
Enzyme-Linked Immunosorbent Assay (ELISA).
Fifty milligrams of mouse liver was homogenized in 1-
mL of a lysis buffer containing protease inhibitors.
The protein concentration was measured, and the sam-
ples were adjusted to the same protein concentrations.
KC and MIP2 were measured with Quantikine murine
ELISA kits (R&D Systems) according to the manufac-
turer’s instructions. The KC and MIP2 concentrations
were calculated per gram of liver protein.
Statistical Analysis. All data are expressed as means
and standard errors of the mean. Statistical calculations
were performed with GraphPad Prism 5 (GraphPad
Software, Inc., CA) on a Macintosh PowerBook G4
computer. Statistical analysis was performed with an
unpaired Student t test or two-way analysis of var-
iance. Differences were considered significant if P was
less than 0.05. Survival rates are presented with
Kaplan-Meier curves, and significance was calculated
with the log-rank test.
Results
CXCR2 Knockout Mice Treated with APAP Have
a Lower Mortality Rate than Wild-Type Mice. Wild-
type mice (n ¼ 17) and knockout mice (n ¼ 27)
received 750 mg/kg APAP; their mortality was
recorded every 24 hours for 5 days. Although CXCR2
wild-type mice had a higher mortality rate than
CXCR2 knockout mice, this did not reach statistical
significance (Fig. 1). Although previous experiments
have suggested that 750 mg/kg APAP is the median le-
thal dose, neither group in this study reached this
mortality rate, and this is likely why the differences
did not reach statistical significance. Therefore, addi-
tional wild-type mice (n ¼ 11) and knockout mice
(n ¼ 15) were treated with 1000 mg/kg APAP, and
their mortality was measured every 24 hours for 5
days. At this increased APAP dose, the mortality rate
of wild-type mice was significantly higher than that of
CXCR2 knockout mice (Fig. 1A; P < 0.01).
Serum AST and ALT Are Lower in CXCR2
Knockout Mice Versus Wild-Type Mice After APAP.
Because APAP is a hepatotoxic agent, serum AST (Fig.
1B) and ALT (Fig. 1C) were measured in knockout
and wild-type mice after APAP or PBS administration.
AST and ALT peaked at 24 hours, returned to the
baseline at 72 hours, and were significantly lower in
CXCR2 knockout mice versus wild-type mice at 24
and 48 hours. This suggests that APAP treatment in
CXCR2 knockout mice caused less liver injury in
comparison with wild-type mice, and this provides
some explanation for the lower mortality rate in
knockout mice.
Less Hepatocyte Apoptosis Is Seen After APAP in
CXCR2 Knockout Mice Versus Wild-Type Mice. Liver
injury was also investigated through the measurement
Fig. 1. (A) Mortality rate of CXCR2 knockout (KO) mice versus wild-
type (WT) mice after the intraperitoneal administration of 750 or 1000
mg/kg APAP. The number of surviving animals was measured every
24 hours for 5 days. The survival curves were generated with Kaplan-
Meier analysis (*P < 0.01 versus KO animals receiving the same
APAP dose). (B) Serum ALT and (C) AST in CXCR2 KO and WT mice
treated with 375 mg/kg APAP or PBS (control). Serum was collected
at 24, 48, and 72 hours, and serum ALT and AST activities were deter-
mined (n  5 per group). CXCR2 KO mice had significantly lower ALT
and AST levels at 24 and 48 hours (P < 0.05) in comparison with
WT mice.
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of hepatocyte apoptosis with TUNEL staining and
DNA fragmentation analysis. Less apoptosis was seen
16 hours after APAP in CXCR2 knockout mice (Fig.
2A,B) versus wild-type mice. The percentage of hepa-
tocyte apoptosis in CXCR2 knockout mice (n ¼ 9,
13.95% 6 2.03%) was significantly lower than that in
wild-type mice (n ¼ 9, 30.39% 6 3.45%, P < 0.01;
Fig. 2E). Thus, less apoptosis in CXCR2 knockout
mice after APAP may be a possible mechanism for the
lower mortality rate after lethal APAP dosing in
CXCR2 knockout mice. To verify that apoptosis was
important in this liver injury, additional mice received
Q-VD-OPh. TUNEL staining demonstrated signifi-
cantly less hepatocyte apoptosis in both wild-type mice
(2.37% 6 0.5%, n ¼ 6) and knockout mice (2.13%
6 0.41%, n ¼ 6; Fig. 2C-E) receiving this caspase
Fig. 2. (A,C) Wild-type (WT) mice and (B,D) CXCR2 knockout (KO) mice were treated with 375 mg/kg APAP (C,D) with or (A,B) without treat-
ment with the pancaspase inhibitor Q-VD-OPh; they were sacrificed at 16 hours, and hepatocyte apoptosis was assessed by TUNEL staining
(400). (E) TUNEL-positive cells were counted, and the percentage of positive cells is illustrated (**P < 0.01, n ¼ 6-9 mice per group). (F)
DNA fragmentation confirmed the TUNEL staining findings (lane M presents the DNA molecular marker control). (E) The percentage of hepatocyte
apoptosis in CXCR2 KO mice (n ¼ 9, 13.95% 6 2.03%) was significantly lower than that in WT mice (n ¼ 9, 30.39% 6 3.45%, **P <
0.01); these animals did not receive any pretreatment with Q-VD-OPh. This suggests that a decrease in apoptosis in CXCR2 KO mice in response
to APAP toxicity may be one of the mechanisms responsible for the decrease in the mortality rate after lethal APAP dosing in CXCR2 KO mice
versus WT mice. To verify that apoptosis was playing a significant role in the liver injury in this model, additional mice received the pancaspase
inhibitor Q-VD-OPh (50 mg/kg) in addition to APAP. TUNEL staining demonstrated significantly less apoptosis in the livers of (C) WT mice and
(D) KO mice receiving the caspase inhibitor with APAP. (E) TUNEL-positive cells were significantly decreased in the livers of both WT (2.37% 6
0.5%, n ¼ 6) and KO mice (2.13 6 0.41%, n ¼ 6) receiving Q-VD-OPh and APAP in comparison with animals receiving APAP alone. (F) DNA
fragmentation studies confirmed these findings.
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inhibitor and APAP. DNA fragmentation studies con-
firmed this finding (Fig. 2F).
There Is No Difference in Hepatocyte Prolifera-
tion Between CXCR2 Knockout and Wild-Type Mice
After APAP. To determine whether differences in he-
patocyte proliferation between wild-type and knockout
mice might account for the differences observed in
mortality, hepatocyte proliferation after APAP was
measured by hepatocyte BrdU incorporation (Fig. 3A).
BrdU incorporation peaked at 48 hours in both
groups. Although wild-type mice had a slightly higher
hepatocyte proliferation rate than knockout mice, this
did not reach statistical significance.
There Is No Difference in Hepatic GSH Depletion
in CXCR2 Knockout Mice Versus Wild-Type Mice
After APAP. To investigate whether CXCR2 signaling
affects APAP metabolism, we measured the hepatic
GSH concentration in wild-type and CXCR2 knock-
out mice after the administration of 375 mg/kg APAP
at different time points (Fig. 3B). GSH concentrations
decreased within 1 hour of APAP administration and
began to rebound within 24 hours. No significant dif-
ferences were seen in hepatic GSH concentrations in
wild-type mice versus CXCR2 knockout mice; this
suggested that CXCR2 signaling does not affect APAP
metabolism.
APAP Treatment Causes Hepatic Caspase-3 and
Caspase-9 Activation. Apoptosis is dependent on cas-
pase activation. Because there is less apoptosis after
APAP toxicity in knockout mice versus wild-type
mice, we examined hepatic caspase-3 and caspase-9 ac-
tivity 1, 2, 4, and 8 hours after APAP administration.
According to western blot analysis, hepatic caspase-3
and caspase-9 were activated in both wild-type and
CXCR2 knockout mice within 1 hour of APAP
administration (Fig. 4). Although no differences were
seen in activated caspase-9 between knockout and
wild-type mice (Fig. 4A,B), activated hepatic caspase-3
levels were undetectable in knockout mice, in contrast
to obvious levels in wild-type mice (P < 0.05 at all
time points; Fig. 4C,D).
XIAP Is Increased in CXCR2 Knockout Mice After
APAP Administration. Because there was a difference
in apoptosis after APAP dosing in CXCR2 knockout
mice versus wild-type controls as well as differences in
caspase-3 activation, we next investigated if there were
differences in prosurvival protein expression after
APAP administration. Western blotting for the antia-
poptotic proteins cIAP2, XIAP, Bcl-2, and Bcl-XL was
performed on hepatic tissues 1, 2, 4, and 6 or 8 hours
after APAP administration. There were no differences
in hepatic Bcl-2 or Bcl-XL expression (Fig. 5A-C). In
contrast, cIAP2 expression increased in wild-type and
CXCR2 knockout mice after APAP, with significant
increases seen within 1 to 2 hours of APAP dosing;
levels decreased to the baseline by 6 hours after APAP
(Fig. 5D,E). Although significant cIAP increases were
seen in wild-type and CXCR2 knockout mice with
respect to control animals, there were no significant
differences in cIAP levels in wild-type mice versus
knockout mice at any time point. XIAP demonstrated
the most significant differences in survival protein expres-
sion. Wild-type mice expressed minimal XIAP in
response to APAP. In contrast, significant hepatic XIAP
expression was seen after APAP in CXCR2 knockout
mice (P < 0.01 at 2 and 4 hours; Fig. 5D,F).
Hepatic NF-jB p52 Is Activated in CXCR2
Knockout Mice After APAP Administration. XIAP
up-regulation is controlled by activation of NF-jB
p65 and p52.11,12 To investigate if hepatic NF-jB
p65 was activated in mice after APAP administration,
we measured phosphorylated NF-jB p65 by immu-
noprecipitation and immunoblotting at various time
points after APAP dosing. There was no evidence of
Fig. 3. (A) In vivo hepatocyte proliferation after APAP treatment in
CXCR2 knockout (KO) and wild-type (WT) mice was measured via
BrdU incorporation at various time points (n  4 per group). Although
WT mice had a slightly higher proliferation rate at all time points,
none of these differences achieved statistical significance. (B) Liver
GSH levels were measured after APAP treatment in WT and CXCR2 KO
mice (n ¼ 4-8 mice per group); no differences in GSH levels were
detected between the two groups.
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activated hepatic NF-jB p65 in wild-type or CXCR2
knockout mice after APAP (Fig. 6A). Next, we meas-
ured hepatic cytoplasmic and nuclear NF-jB p52 in
knockout or wild-type mice after APAP. There was
significant NF-jB p52 expression in both the cyto-
plasmic and nuclear hepatic proteins from CXCR2
knockout mice treated with APAP. There was no de-
tectable hepatic NF-jB p52 after APAP in wild-type
mice (Fig. 6B-D).
APAP Induces Hepatic JNK Activation in Wild-
Type and CXCR2 Knockout Mice. We examined he-
patic JNK expression in wild-type and CXCR2 knock-
out mice after the administration of 375 mg/kg APAP
to investigate whether CXCR2 signaling causes JNK
activation. CXCR2 knockout and wild-type mice had
a significant JNK increase after APAP. Hepatic JNK
activation in wild types peaked 1 hour after APAP
administration, gradually declined, and returned to the
baseline at 12 hours; JNK activation in CXCR2
knockout mice was slower and weaker than that in
wild-type mice (Fig. 6E,F). Less JNK activation was
seen in CXCR2 knockout mice versus wild-type mice;
this was statistically significant at 1 hour (P < 0.05).
CXCR2 Expression on Mouse Hepatocytes. To
determine whether the effects of CXCR2 signaling
occur directly within hepatocytes rather than indirectly
on other cell types within the liver, we measured
CXCR2 expression on primary mouse hepatocytes; we
used mouse neutrophils as a positive control because
these cells are well known to express CXCR2. RT-
PCR was performed with a pair of primers located in
exon 2 (data not shown). These experiments confirmed
CXCR2 expression on wild-type hepatocytes and neu-
trophils and no CXCR2 expression on CXCR2 knock-
out hepatocytes and neutrophils (data not shown). To
exclude the possibility of contamination by genomic
DNA, we designed a second pair of primers that
crossed exon 1 and exon 2. These experiments con-
firmed that wild-type hepatocytes and neutrophils
expressed CXCR2 (Fig. 7A); CXCR2 knockout hepa-
tocytes did not express any detectable CXCR2.
Flow cytometry confirmed these results (Fig. 7B,C).
Wild-type hepatocytes expressed low CXCR2 levels.
There was no CXCR2 expression on knockout mouse
hepatocytes. The mean fluorescence intensity (MFI) of
CXCR2 on wild-type hepatocytes (5.26% 6 0.33%)
Fig. 4. Western blot analysis for activated hepatic caspase-3 and caspase-9 1, 2, 4, and 8 hours after APAP treatment in wild-type (WT) and
CXCR2 knockout (KO) mice: (A,B) activated caspase-9 and (C,D) activated caspase-3. There were no differences in activated caspase-9 between
WT and KO mice; in contrast, there were significant differences between levels of activated caspase-3 at all time points in WT mice versus
CXCR2 KO mice (P < 0.05 for all time points). GAPDH levels demonstrated equal loading of the gels. Experiments were performed at least three
times with similar results.
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was significantly increased (Fig. 7D) versus knockout
mouse hepatocytes (3.42% 6 0.37%, P < 0.05). MFI
of hepatocyte CXCR2 expression in wild-type mice 3
hours after APAP dosing was the same as that of
untreated hepatocytes, and this suggested that APAP
treatment does not change hepatocyte CXCR2 expres-
sion in wild-type mice (Fig. 7D).
KC and MIP2 Expression Is Increased in CXCR2
Knockout Mice After APAP Administration. Our
results suggest that CXCR2 signaling facilitates apopto-
sis after APAP dosing. CXCR2 activation requires that
CXCR2 ligands, which include KC and MIP2, bind to
this receptor. We hypothesized that APAP increases KC
and MIP2 production, so hepatic KC and MIP2 pro-
tein expression was measured in wild-type and knock-
out mice after APAP administration by ELISA (Fig.
8A,B). KC and MIP2 protein levels increased after
APAP and peaked at 4 hours in both wild-type and
knockout mice. KC and MIP2 levels in the CXCR2
knockout mice were significantly higher than those in
the wild-type mice (P < 0.01) at every time point.
Discussion
These experiments show that CXCR2 knockout
mice have a survival advantage over wild-type mice af-
ter a median lethal dose of APAP. The liver injury fol-
lowing APAP in CXCR2 knockout mice is less than
that seen in wild-type mice, and this results in signifi-
cantly lower levels of serum liver enzymes and less liver
injury. Further experiments have suggested that this is
at least partially related to less apoptosis in knockout
Fig. 5. Representative western blots showing hepatic expression of prosurvival proteins in CXCR2 knockout (KO) mice and wild-type (WT) con-
trols treated with APAP. (A-C) Bcl-2 and Bcl-XL protein levels. These showed no change in response to APAP dosing in WT or CXCR2 KO mice. (D-
F) Hepatic cIAP2 and XIAP protein levels. These showed differences in the response to APAP. cIAP2 levels increased in both WT and CXCR2 KO
mice in response to APAP; WT levels were significantly different from those of controls at 2 and 4 hours (**P < 0.01), and KO levels were sig-
nificantly different from those of controls at 2, 4, and 6 hours (*P < 0.05 and **P < 0.01). However, there were no significant differences
between WT and KO mice at any time point. In contrast, significant increases in XIAP levels in CXCR2 KO mice were seen in response to APAP,
whereas no increases in XIAP were seen in response to APAP in WT mice (**P < 0.01). GAPDH levels were shown to demonstrate equal loading
of the gels. Experiments were performed at least three times with similar results.
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mice versus control animals, with no differences in he-
patocyte proliferation. However, the role of apoptosis
in APAP-induced liver injury is controversial, and it is
possible that the less profound GSH depletion seen in
this strain of mouse may allow apoptosis to proceed in
a more significant fashion than that seen in other
models. Although the CXCR2 receptor and its ligands,
the CXC chemokines, are known to mediate the
inflammatory response, these ligand/receptor interac-
tions also modulate proliferation. For example, Bone-
Larson and colleagues demonstrated increased hepato-
cyte proliferation after APAP injury, which was a
CXCR2-dependent response.5 This beneficial prolifera-
tive response is dependent on increased CXCR2
Fig. 6. (A) Activated NF-jB p65 was measured by immunoprecipitation (IP) and immunoblotting (IB) in liver tissues at various time points af-
ter APAP administration; no changes were seen in response to APAP at any time point in either wild-type (WT) or knockout (KO) mice. Next, (B,C)
hepatic cytoplasmic and (B,D) nuclear proteins were extracted, and NF-jB p52 expression was examined at various time points after APAP dos-
ing with western blotting. This demonstrated that hepatic NF-jB p52 was activated in CXCR2 KO mice in both cytoplasmic and nuclear compart-
ments after APAP administration and was not detectable in either the cytoplasmic or nuclear proteins in WT mice after APAP (*P < 0.05 and
**P < 0.01 versus WT mice at the same time point and also versus their respective controls). GAPDH was used as a cytoplasmic protein load-
ing control, and fibrillarin was used as a nuclear protein control. (E,F) Next, activated hepatic JNK was measured by western blotting in WT and
CXCR2 KO mice in response to APAP. JNK levels increased significantly in response to APAP in both CXCR2 KO mice and WT mice (*P < 0.05
and **P < 0.01 versus their respective controls). CXCR2 KO mice had less activated hepatic JNK after APAP in comparison with WT mice, and
this reached statistical significance at the 1-hour time point (P < 0.05). Experiments were performed three times with similar results.
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expression.5 The CXC chemokines also have a thera-
peutic role in APAP-induced liver injury.5-7 This con-
flicts with our study, which suggests that the lack of a
CXCR2 receptor/ligand interaction confers a survival
benefit because of a decrease in liver injury from
APAP toxicity.
Investigators have reported findings similar to ours
in an ischemia/reperfusion model of injury.13 Kuboki
and others13 demonstrated that CXCR2 knockout
mice had significantly less liver injury after ischemia/
reperfusion, and this was related to accelerated hepato-
cyte proliferation in the knockout mice. This was asso-
ciated with increased NF-KB and signal transducers
and activators of transcription-3 activation and was
not associated with changes in inflammation.13 These
investigations suggested that low MIP2 concentrations
protected against cell death, whereas high MIP2 con-
centrations induced cell death; these effects were absent
in the CXCR2 knockout mice.13 Similarly, Ishida and
colleagues14 also demonstrated that CXCR2 knockout
mice had a lower mortality rate after APAP injury
than control mice but a higher mortality rate than
neutropenic mice. These findings are similar to ours in
that the CXCR2 knockout genotype confers protection
against hepatic injury. Our experiments did not dem-
onstrate differences in hepatocyte proliferation,
although there were significant decreases in cellular
death, and the NF-jB pathway appeared to be
involved in this process. Our experiments confirm the
presence of the CXCR2 receptor on hepatocytes in the
wild-type mice. The CXCR2 ligands, MIP2 and KC,
were significantly increased after APAP in both wild-
type and CXCR2 knockout mice, with the most sig-
nificant increases seen in the knockout animals. The
increased levels in the knockout animals did not
appear to have any detrimental hepatic effects; this was
similar to the results of Kuboki and colleagues.13
Our experiments suggest that the survival advantage
conferred by the CXCR2 knockout genotype is related
to decreased hepatocyte apoptosis. This was confirmed
by a decrease in activated caspase-3 and increases in
the prosurvival protein XIAP in CXCR2 knockout
mice, and this provides a potential mechanism for
decreased apoptosis. The IAP family of proteins pro-
tects against apoptosis in many systems, and this is
linked to the BIF domains of these molecules, which
bind to and inhibit caspases.3 In our model, this links
the decrease in activated caspase-3 to the increased
XIAP levels in the knockout mice. XIAP is known to
potently inhibit caspase-3, caspase-7, and caspase-9,
and this also correlates with our data.15
Another mechanism for XIAP-conferred protection
against apoptosis is a positive feedback mechanism by
which XIAP induces NF-jB with the additional
recruitment of other target genes.4 XIAP as well as
cIAP can activate NF-jB. cIAP is also up-regulated in
our model, although this was seen in wild-type and
knockout mice, so it does not provide as much of a
clear explanation of the differences in these two geno-
types.4 Another interesting aspect regarding XIAP
Fig. 7. (A) RT-PCR for CXCR2. Wild-type
(WT) hepatocytes and neutrophils demon-
strated obvious levels of CXCR2, whereas
there were no detectable levels for hepato-
cytes or neutrophils from the CXCR2 knockout
(KO) mice. GAPDH was used as a loading
control. (B,C) Flow cytometry for cells express-
ing CXCR2. The cells were stained with phy-
coerythrin-conjugated isotype IgG (red line) or
CXCR2 (green line). Representative histograms
are shown for CXCR2 expression on (B) KO
mouse hepatocytes and (C) WT mouse hepa-
tocytes. (D) Quantitative CXCR2 expression
using flow cytometry analysis by MFI (n ¼ 6-
12 mice per group, *P ¼ 0.0015). WT mouse
hepatocytes expressed low levels of CXCR2;
this did not change after treatment with APAP.
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effects was demonstrated by Levkau and colleagues,3
who showed that XIAP overexpression inhibits cell
proliferation; this may suppress the cell cycle and pre-
vent cells from exiting G0/G1 into phases of the cell
cycle that are more vulnerable to apoptotic signals.
Although the classical NF-jB activation pathway is
important in many cellular processes, the noncanonical
NF-jB pathway is also important for normal and
pathological processes. NF-jB is restricted to the cyto-
plasm by inhibitory proteins that are degraded when
they are specifically phosphorylated; this permits NF-
jB to enter the nucleus and activate target genes. Dif-
ferent combinations of NF-jB subunits induce tran-
scription with different timing sequences and recognize
different sequences of NF-jB binding sites. The non-
canonical pathway is based on processing of the NF-
jB2 gene product p100.11,12 The p52 subunit is gen-
erated from p100 processing by I kappa B kinase
alpha, one of the kinase complexes.11,12 Once pro-
duced, p52 can enter the nucleus and induce genes
that regulate many processes.12 In other systems,
including androgen-sensitive LNCaP cells in vitro and
lymphoma cells, NF-jB/p52 encourages cellular
growth by protecting cells from apoptosis and stimu-
lating cyclin D1 expression.16,17 Coculturing of bone
marrow stromal cells with lymphoma cells resulted in
active p52 generation, which then translocated to the
nucleus and was associated with increased XIAP and
cIAP expression; this was similar to what was seen in
our system.17
Investigators have shown a significant relationship
between NF-KB, XIAP, and the JNK cascade.18-20
Bubici and colleagues18 showed that NF-KB–mediated
apoptosis suppression involves inhibition of the JNK
cascade, which is related to up-regulation of a variety
of mediators, including XIAP, which block aspects of
the JNK cascade. Similarly, Kaur and colleagues20
showed that XIAP inhibits JNK activation by trans-
forming growth factor b1 and counteracts transform-
ing growth factor b1–induced apoptosis. This is con-
sistent with our findings, in which CXCR2 knockout
mice increased XIAP levels, decreased JNK levels, and
decreased apoptosis and mortality. Other investigators
have used leflunomide with APAP toxicity and have
shown a protective effect due to the inhibition of
APAP-induced JNK activation. This decreased Bcl-2
and Bcl-XL activation and decreased apoptosis.19 This
is also consistent with our studies. In contrast, other
investigators have shown that APAP-induced activation
of JNK promotes necrosis by a direct effect on
mitochondria.21,22
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